Sartorius Stedim Biotech
€208.20Change from previous close: +0.97%Absolute change: +€2.00
At a glance
- Revenue growth
- +6.74%
- 2025 vs 2024
- Net income growth
- +51.68%
- 2025 vs 2024
- Net margin
- 9.0%
- 2024: 6.3%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 148 | 193 | 247 | — | 125 | 120 |
| Depreciation and amortization | 79.4 | 81.1 | 83.9 | — | 77.9 | 77.4 |
| Capital expenditure | -72.8 | -69.6 | -117 | — | -75.9 | -65.3 |
| Investing cash flow | -72.8 | -69.6 | -119 | — | -76.9 | -65.3 |
| Financing cash flow | -395 | -29.2 | 0.9 | -465 | -53.2 | — |
| Dividends paid | — | — | 0.0 | — | — | — |
| Share repurchases | 2.4 | -2.9 | — | — | 1.1 | -2.0 |
| Debt issued | 295 | 0.0 | 0.4 | — | 12.9 | 0.0 |
| Debt repaid | -536 | -14.7 | 0.0 | — | 0.0 | -13.7 |
| Effect of exchange rates | 2.2 | 0.5 | -1.2 | — | -3.0 | -0.3 |
| Net change in cash | -320 | 94.5 | 129 | -401 | -5.2 | — |
| Free cash flow | 75.1 | 124 | 129 | — | 49.0 | 54.5 |